- Home
- JLL vs INSM Comparison
JLL vs INSM Comparison
Compare JLL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLL
- INSM
- Stock Information
- Founded
- JLL 1997
- INSM 1988
- Country
- JLL United States
- INSM United States
- Employees
- JLL N/A
- INSM N/A
- Industry
- JLL Real Estate
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- JLL Finance
- INSM Health Care
- Exchange
- JLL Nasdaq
- INSM Nasdaq
- Market Cap
- JLL 13.1B
- INSM 14.3B
- IPO Year
- JLL 1997
- INSM 2000
- Fundamental
- Price
- JLL $262.06
- INSM $81.06
- Analyst Decision
- JLL Strong Buy
- INSM Strong Buy
- Analyst Count
- JLL 7
- INSM 15
- Target Price
- JLL $309.00
- INSM $92.00
- AVG Volume (30 Days)
- JLL 377.2K
- INSM 1.8M
- Earning Date
- JLL 02-19-2025
- INSM 02-20-2025
- Dividend Yield
- JLL N/A
- INSM N/A
- EPS Growth
- JLL 141.97
- INSM N/A
- EPS
- JLL 11.30
- INSM N/A
- Revenue
- JLL $23,432,900,000.00
- INSM $363,707,000.00
- Revenue This Year
- JLL N/A
- INSM $20.03
- Revenue Next Year
- JLL $10.34
- INSM $41.61
- P/E Ratio
- JLL $23.19
- INSM N/A
- Revenue Growth
- JLL 12.87
- INSM 19.17
- 52 Week Low
- JLL $171.45
- INSM $21.92
- 52 Week High
- JLL $288.50
- INSM $84.87
- Technical
- Relative Strength Index (RSI)
- JLL 40.08
- INSM 58.18
- Support Level
- JLL $268.02
- INSM $79.50
- Resistance Level
- JLL $286.00
- INSM $80.28
- Average True Range (ATR)
- JLL 7.87
- INSM 2.98
- MACD
- JLL -2.02
- INSM 0.06
- Stochastic Oscillator
- JLL 8.39
- INSM 63.38
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.